secwatch.observer — SEC 8-K summary
======================================

Issuer:     SRx Health Solutions, Inc. (SRXH)
CIK:        0001471727
Form:       8-K
Filed at:   2026-10-07T12:05:25+00:00
Accession:  0001493152-26-046085
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

SRX Global to acquire CERo Therapeutics unit in $1M stock deal, forgiving $8.25M note
--------------------------------------------------------------------------------

- SRX will issue Holdings $1,000,000 of common stock, priced at the lower of the pre-signing close or 20-day VWAP on the NYSE American, and forgive the Consolidated Note.
- Debt relief covers the note's up to $11,666,108.77 original principal ($8,249,643.77 outstanding) plus interest; SRX assumes ~$1,562,000 of liabilities.
- A 30-day go-shop lets Holdings solicit rival bids via Joseph Gunnar & Co.; a Superior Proposal must close by March 15, 2027 and repay the Secured Note.
- Holdings owes a $750,000 termination fee; SRX owes Holdings $750,000 if it fails to fund; Buyer expense reimbursement is capped at $100,000.
- Closing requires Series A preferred consents/conversion plus acquisition of Holdings' Series C, D and E preferred; 180-day lock-ups and key-employee pacts are contemplated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1471727/000149315226046085/0001493152-26-046085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1471727/000149315226046085/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-046085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer